Hye Jin Choi

Hye Jin Choi

Auto-generated profile, based on publicly available information

Hye Jin Choi

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
JLJeeyun Lee
Jeeyun Lee
SPSe Hoon Park
Se Hoon Park
HCHeung-Moon Chang
Heung-Moon Chang
JKJun Suk Kim
Jun Suk Kim
HCHye Jin Choi
Hye Jin Choi
HLHo Yeong Lim
Ho Yeong Lim

7 April 2014 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
JLJeong Won Lee
Jeong Won Lee
CKChang Moo Kang
Chang Moo Kang
HCHye Jin Choi
Hye Jin Choi
WLWoo Jung Lee
Woo Jung Lee
SSSong si young Song
Song si young Song
JLJong Doo Lee
Jong Doo Lee
In this study, we aimed to assess the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) measured on 18F-FDG PET/CT in pancreatic cancer patients who underwent resection with curative intent. Methods: Eighty-seven patients with pancreatic ductal adenocarcinoma who underwent 18F-FDG PET/CT and subsequent surgical resection with curative intent with (30 patients) or without (57 patients) neoadjuvant therapy were retrospectively enrolled. The maximum standardized uptake value (SUVmax), MTV, and TLG were measured on 18F-FDG PET/CT in all patients. The prognostic significances of PET/CT parameters and tumor factors for recurrence-free survival (RFS) and overall survival (OS) were evaluated by univariate and multivariate analyses. Results: Of the 87 patients, 57 (64%) experienced recurrence during the follow-up period. The tumor size, pathologic T (pT) stage, SUVmax, MTV, and TLG were significant prognostic factors for both RFS and OS (P < 0.05) on univariate analyses, and the presence of lymph node metastasis showed significance only for predicting RFS (P < 0.05). On multivariate analyses, the tumor size, MTV, and TLG were independent prognostic factors for RFS, and pT stage, MTV, and TLG were independent prognostic factors for OS. For the 57 patients who did not undergo neoadjuvant treatment, MTV and TLG remained significant predictive factors for tumor recurrence, along with tumor size and SUVmax. Conclusion: MTV and TLG are independent prognostic factors for predicting RFS and OS in patients with pancreatic cancer. Thus, 18F-FDG PET/CT can provide useful prognostic information for patients undergoing resection of pancreatic cancer with curative intent irrespective of neoadjuvant treatment.

1 February 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
CKChang Gon Kim
Chang Gon Kim
CKChan Kim
Chan Kim
SYSang Eun Yoon
Sang Eun Yoon
KKKyung Hwan Kim
Kyung Hwan Kim
SCSeong Jin Choi
Seong Jin Choi
HLHo Yeong Lim
Ho Yeong Lim

5 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WKWon Kyu Kim
Won Kyu Kim
YKYujin Kwon
Yujin Kwon
MJMi Jang
Mi Jang
MPMinhee Park
Minhee Park
JKJiyoon Kim
Jiyoon Kim
HKHoguen Kim
Hoguen Kim
WNT signaling activation in colorectal cancers (CRCs) occurs through APC inactivation or β-catenin mutations. Both processes promote β-catenin nuclear accumulation, which up-regulates epithelial-to-mesenchymal transition (EMT). We investigated β-catenin localization, transcriptome, and phenotypic differences of HCT116 cells containing a wild-type (HCT116-WT) or mutant β-catenin allele (HCT116-MT), or parental cells with both WT and mutant alleles (HCT116-P). We then analyzed β-catenin expression and associated phenotypes in CRC tissues. Wild-type β-catenin showed membranous localization, whereas mutant showed nuclear localization; both nuclear and non-nuclear localization were observed in HCT116-P. Microarray analysis revealed down-regulation of Claudin-7 and E-cadherin in HCT116-MT vs. HCT116-WT. Claudin-7 was also down-regulated in HCT116-P vs. HCT116-WT without E-cadherin dysregulation. We found that ZEB1 is a critical EMT factor for mutant β-catenin-mediated loss of E-cadherin and Claudin-7 in HCT116-P and HCT116-MT cells. We also demonstrated that E-cadherin binds to both WT and mutant β-catenin, and loss of E-cadherin releases β-catenin from the cell membrane and leads to its degradation. Alteration of Claudin-7, as well as both Claudin-7 and E-cadherin respectively caused tight junction (TJ) impairment in HCT116-P, and dual loss of TJs and adherens junctions (AJs) in HCT116-MT. TJ loss increased cell motility, and subsequent AJ loss further up-regulated that. Immunohistochemistry analysis of 101 CRCs revealed high (14.9%), low (52.5%), and undetectable (32.6%) β-catenin nuclear expression, and high β-catenin nuclear expression was significantly correlated with overall survival of CRC patients (P = 0.009). Our findings suggest that β-catenin activation induces EMT progression by modifying cell-cell junctions, and thereby contributes to CRC aggressiveness.

1 February 2007 in Molecular Therapy
Verified
Journal Article
Open access
JYJi Young Yoo
Ji Young Yoo
JKJoo-Hang Kim
Joo-Hang Kim
YKYoung-Guen Kwon
Young-Guen Kwon
EKEok-Cheon Kim
Eok-Cheon Kim
NKNam Kyu Kim
Nam Kyu Kim
Chae-Ok YunChae-Ok Yun
Chae-Ok Yun
RNA interference is being developed to treat cancer. Although highly target specific, its use has been limited by its short duration of expression. To overcome this shortcoming, we constructed an oncolytic adenovirus (Ad)-based short hairpin RNA (shRNA) expression system (Ad-B7-shVEGF) against vascular endothelial growth factor (VEGF), a key mediator in angiogenesis. To demonstrate the VEGF-specific nature of this Ad-based shRNA, replication-incompetent Ad expressing VEGF-specific shRNA (Ad-E1-shVEGF) was also generated. Ad-E1-shVEGF was highly effective in reducing VEGF expression, and elicited an antiangiogenic effect in vitro and in vivo. Similarly, Ad-B7-shVEGF exhibited potent antiangiogenic effects in the matrigel plug assay. Moreover, Ad-B7-shVEGF demonstrated a greater antitumor effect and enhanced survival compared to the cognate control oncolytic Ad, Ad-B7. Ad-B7-shVEGF induced significant reduction in tumor vasculature, verifying the antiangiogenic mechanism. Furthermore, both the duration and magnitude of gene silencing by Ad-B7-shVEGF was greater than Ad-E1-shVEGF. These results suggest that the combined effects of oncolytic viral therapy and cancer cell-specific expression of VEGF-targeted shRNA elicits greater antitumor effect than an oncolytic Ad alone.

31 October 2022 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
CLChoong-Kun Lee
Choong-Kun Lee
HCHong Jae Chon
Hong Jae Chon
JCJaekyung Cheon
Jaekyung Cheon
MLMyung Ah Lee
Myung Ah Lee
HIHyeon-Su Im
Hyeon-Su Im
HCHye Jin Choi
Hye Jin Choi